The short version of lyophilized powder fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-03. Anything still debated is marked as such rather than presented as settled.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
== External links == "Benzydamine oral rinse". Medicinenet. "Difflam spray (benzydamine)". Net Doctor, UK. 8 March 2020. Archived from the original on 22 December 2006. Retrieved 30 December 2006. "Tantum Verde (benzydamine)". Carysfort Healthcare Limited, Ireland. Archived from the original on 2015-11-25.
In February 2005, Bagwell and Biggio were jointly inducted into the Texas Sports Hall of Fame. Shortly after the 2005 season began, the chronic arthritic condition in his shoulder that had begun in 2001 finally sidelined him, rendering him inactive for three-quarters of the season. The former Gold Glove winner was now a defensive liability with a severely limited throwing arm; he had to "push" the ball instead of throwing it. Teams began taking advantage of his defensive weakness. Once possessing great ability to throw out the lead runner at third base ahead on bunt plays, Bagwell found it difficult to practice with the other infielders between innings. Concurrently, Bagwell's offensive production suffered, and pressure mounted on Astros management to bench the perennial All-Star; the club had started the season with a 15–30 won–loss record. He hit his last major league home run against Maddux on April 29, tying him for the most against any pitcher with seven. Bagwell continued to play through the pain until, after going 0-for-5 in a loss to the Pirates on May 4, it became so unbearable that he asked manager Phil Garner to remove him from the lineup the following day. He had hit just .250 with three home runs in 88 at-bats. The Astros placed him on the disabled list a few days later, and shoulder surgery followed. The Astros dramatically improved after their poor start to finish 74–43 over their final 117 games and capture the NL wild card.
Minelaying submarines of World War I and World War II were specially built for that purpose. Modern submarine-laid mines, such as the British Mark 5 Stonefish and Mark 6 Sea Urchin, can be deployed from a submarine's torpedo tubes. After World War II, both the US and the USSR experimented with submarine-launched cruise missiles such as the SSM-N-8 Regulus and P-5 Pyatyorka. Such missiles required the submarine to surface to fire its missiles. They were the forerunners of modern submarine-launched cruise missiles, which can be fired from the torpedo tubes of submerged submarines, for example, the US BGM-109 Tomahawk and Russian RPK-2 Viyuga and versions of surface-to-surface anti-ship missiles such as the Exocet and Harpoon, encapsulated for submarine launch. Ballistic missiles can also be fired from a submarine's torpedo tubes, for example, missiles such as the anti-submarine SUBROC. With internal volume as limited as ever and the desire to carry heavier warloads, the idea of the external launch tube was revived, usually for encapsulated missiles, with such tubes being placed between the internal pressure and outer streamlined hulls. Guided torpedoes also proliferated extensively during and after World War II, even further increasing the combat endurance and lethality of submarines and allowing them to engage other submarines at depth (with the latter now being one of the primary missions of the modern attack submarine).
Sources: en.wikipedia.org
Those with mass 5 decay to helium-4 and a proton or a neutron, and those with mass 8 decay to two helium-4 nuclei; their half-lives (helium-5, lithium-5, and beryllium-8) are very short, unlike the half-lives for all other such nuclides with A ≤ 209, which are very long. (Such nuclides with A ≤ 209 are primordial nuclides except 146Sm.) Working out the details of the theory leads to an equation relating the half-life of a radioisotope to the decay energy of its alpha particles, a theoretical derivation of the empirical Geiger–Nuttall law.
=== HIV/AIDS-associated diarrhea === In a randomized controlled trial involving patients with advanced HIV/AIDS, S. boulardii supplementation was associated with a higher recovery rate from chronic diarrhea compared with placebo. Participants receiving S. boulardii also experienced weight gain, whereas those in the placebo group lost weight over the 18-month study period. No adverse reactions were reported in this immunocompromised population
== Evolutionary Biology == The following tables compare the Homo sapiens FGFR1OP2 gene and protein to orthologs. In both of the following tables, the divergence from the Homo sapiens FGFR1OP2 gene or protein to the ortholog was found using TimeTree. Ortholog mRNA and protein sequences were found using NCBI's BLAST and UCSC's BLAT Tool. The accession numbers, as well as the sequence length and the sequence similarity were compiled using BLAST.
Patrick Brenan, Finance Director, Minories Finance Ltd. For services to Banking. Linda Broadhead, Senior Management Pay Band 2, the Employment Service, Department for Education and Employment. Rosemary Anne Brown, Member, Occupational Pensions Board. For services to Pensions Legislation. Barbara Kathleen Bryant, Grade 7, Department of Social Security. Keith Patrick Burke, Managing Director, Dana Spicer Europe Ltd., Dana Corporation. For services to Industry and to the Environment. David Burnett. For services to the Development and Application of Biochemistry to Health Care. William John Burnison. For public service. Derek Harold Calam, Member and Vice Chairman, British Pharmacopoeia Commission. For services to the Control of Medicines. Libby Campbell, Executive Director, Nursing and Quality, West Lothian NHS Trust. For services to Health Care. Dennis Duncan Carmichael, Honorary Treasurer, Lawn Tennis Association. For services to Lawn Tennis. Enid Castle, lately Principal, Cheltenham Ladies' College. For services to Education. Jonathan Joseph Chadwick, Secretary to the Imperial War Museum. Christopher Charlton, Director, Cromford Mill Project, Derbyshire. For services to Conservation. Professor Dennis Child. For services to Deaf People. Edward Samuel Childs, Executive Producer, Carlton UK Television. For services to Television Broadcasting. Brian James Clark, Principal Specialist Inspector, Health and Safety Executive, Department of the Environment. Harold Clarke, District Inspector, Board of Inland Revenue. Seamus Anthony Close. For public service.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.